Journal
FRONTIERS IN MOLECULAR NEUROSCIENCE
Volume 15, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnmol.2022.927334
Keywords
intracerebral hemorrhage; brain edema; deferoxamine; iron overload; neuronal death
Categories
Funding
- National Key Research and Development Program of China [2018YFC1312200]
- National Natural Science Foundation of China [82071331, 81870942, 81520108011]
- China Postdoctoral Science Foundation [2020TQ0289, 2020M672291]
- Canadian Institutes of Health Sciences
Ask authors/readers for more resources
This review summarizes recent progress in understanding the mechanisms by which deferoxamine may alleviate intracerebral hemorrhage (ICH) and discusses the potential clinical utility of deferoxamine.
Intracerebral hemorrhage (ICH) is a subtype of stroke that is characterized by high morbidity and mortality, for which clinical outcome remains poor. An extensive literature indicates that the release of ferrous iron from ruptured erythrocytes in the hematoma is a key pathogenic factor in ICH-induced brain injury. Deferoxamine is an FDA-approved iron chelator that has the capacity to penetrate the blood-brain barrier after systemic administration and binds to iron. Previous animal studies have shown that deferoxamine attenuates ICH-induced brain edema, neuronal death, and neurological deficits. This review summarizes recent progress of the mechanisms by which deferoxamine may alleviate ICH and discusses further studies on its clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available